Antibody ID	ANTI0VMPZW
Antibody Name	Anti-PSMA-HC41
Synonyms	Anti-PSMA-HC41    Click to Show/Hide
Antigen Name	Glutamate carboxypeptidase 2 (FOLH1)					Antigen Info
Click to Show/Hide the Sequence Information of This Antibody

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.25 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.26 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.37 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.47 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.48 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.52 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.4 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.07 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	100 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Ref 1	Non-linear self-immolative linkers and conjugates thereof